Company intelligence / Profile preview

deepCDR Biologics

Basel, Basel-Stadt, Switzerland

Ownership: Private
Development stage: Other

Overview

deepCDR Biologics’ platform generates thousands of optimized antibody candidates in months, markedly reducing the time and cost versus traditional methods. They have delivered potent antibodies for cancer, autoimmune diseases, and infectious diseases, including COVID-19. No clinical trial results disclosed; company operates as discovery/engineering partner

Therapeutic areas: OncologyInfectious DiseasesImmunology
Modalities: Monoclonal antibodyBiologicAntibody
Industry: Drug Discovery Services

Partnerships

Alloy Therapeutics (ecosystem/network: >100 global partners)Multiple unnamed biotech/pharma partners for discovery services

Beyond the preview

Go deeper on deepCDR Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on deepCDR Biologics.

Explore the full profile